Skip to main content
SpringerLink
Log in

Elevated Serum Cholesterol in Asymptomatic Adults

  • Chapter
Preventing Disease

Part of the book series: Frontiers of Primary Care ((PRIMARY))

Abstract

Recent clinical trials such as the Lipid Research Clinics (LRC) Coronary Primary Prevention Trial1,2 and, more recently, the Helsinki Heart Study3 have demonstrated that lowering serum cholesterol can reduce the incidence of coronary heart disease (CHD) in middle-aged men with hyperlipidemia. Beginning in 1984, these findings have stimulated the encouragement of the public to consume less dietary fat and the promotion of detection and treatment of persons with hyperlipidemia. Physicians, in particular, received specific guidelines from the National Institutes of Health Consensus Conference on Lowering Blood Cholesterol4 and the National Cholesterol Education Program5 to measure serum cholesterol and prescribe appropriate dietary and/or pharmacologic interventions to reduce serum lipids to a “desirable” level.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lipid Research Clinics Program. Lipid Research Clinics Coronary Primary Prevention Trial results:I.Reduction in incidence of coronary heart disease. JAMA 1984;251:351–64.

    Article  Google Scholar 

  2. Lipid Research Clinics Program. Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365–74.

    Article  Google Scholar 

  3. Frick MH, Elo O, Haapa K, et al. Helsinki Heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–45.

    Article  PubMed  CAS  Google Scholar 

  4. National Institutes of Health. Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–86.

    Article  Google Scholar 

  5. National Institutes of Health. Cholesterol Counts: Steps for Lowering Your Patient’s Blood Cholesterol. NIH Publ. No. 85-2699. Bethesda, Md: 1985.

    Google Scholar 

  6. National Cholesterol Education Program Expert Panel. Report on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36–69.

    Article  Google Scholar 

  7. National Center for Health Statistics. Advancereport of final mortality statistics, 1986. Monthly Vital Statistics Report, Vol. 37, No. 6 (Suppl) DHHS Publ No. (PHS) 88–1120. Hyattsville, Md: Public Health Service, 1988.

    Google Scholar 

  8. National Center for Health Statistics. Health, United States, 1988. DHHS Publ No. (PHS) 89-1232. Washington: Public Health Service, 1986, 41.

    Google Scholar 

  9. Sempos C, Fulwood R, Haines C, et al. The prevalence of high blood cholesterol levels among adults in the United States. JAMA 1989;262:45–52.

    Article  PubMed  CAS  Google Scholar 

  10. Palumbo PJ. Cholesterol lowering for all: a closer look. JAMA 1989;262:91–92.

    Article  PubMed  CAS  Google Scholar 

  11. Wilson PWF, Christiansen JC, Anderson KM, et al. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring study. JAMA 1989;262:41–44.

    Article  PubMed  CAS  Google Scholar 

  12. Brett AS. Treating hypercholesterolemia: how should practicing physicians interpret the published data for patients? N Engl J Med 1989;321:676–79.

    Article  PubMed  CAS  Google Scholar 

  13. Moore TJ. The cholesterol myth. The Atlantic Monthly 1989(Sept): 37–70.

    Google Scholar 

  14. Office of Technology Assessment. Costs and effectiveness of cholesterol screening in the elderly. Washington: 1989.

    Google Scholar 

  15. Garber AM, Sox HC Jr, Littenberg B. Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med 1989;110:622–39.

    PubMed  CAS  Google Scholar 

  16. Ontario Ministry of Health. Task Force on the Use and Provision of Medical Services. Detection and management of asymptomatic hypercholesterolemia. Ottawa: 1989.

    Google Scholar 

  17. Smith WCS, Davis AM, Kenicer MB, et al. Blood cholesterol: is population screening warranted in the UK? Lancet 1989;1:372–73.

    Article  PubMed  CAS  Google Scholar 

  18. Stare FJ. The AMA’s campaign against cholesterol (letter). JAMA 1989;261:3240–41.

    Article  PubMed  CAS  Google Scholar 

  19. Stamler J. Lifestyles, major risk factors, proof and public policy. Circulation 1978;58:3–19.

    PubMed  CAS  Google Scholar 

  20. Stallones RA. Ischemic heart disease and lipids in blood and diet. Annu Rev Nutr 1983;3:155–85.

    Article  PubMed  CAS  Google Scholar 

  21. Grundy SM. Cholesterol and coronary heart disease: a new era. JAMA 1986;256:2849–58.

    Article  PubMed  CAS  Google Scholar 

  22. Dayton S, Pearce ML, Hashimoto S, et al. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969;40:(suppl 2):1–63.

    Google Scholar 

  23. Borhani NO. Primary prevention of coronary heart disease: a critique. Am J Cardiol 1977;40:251–59.

    Article  PubMed  CAS  Google Scholar 

  24. Hjermann I, Velve Byre K, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial in healthy men. Lancet 1981;2:1303–10.

    Article  PubMed  CAS  Google Scholar 

  25. Ahrens EH. The diet-heart question in 1985: has it really been settled? Lancet 1985;1:1085–89.

    Article  PubMed  Google Scholar 

  26. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982;248:1465–77.

    Article  Google Scholar 

  27. World Health Organization, European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancet 1986;1:869–72.

    Google Scholar 

  28. Rinzler S. Primary prevention of coronary heart disease by diet. Bull NY Acad Med 1968;44:936–49.

    CAS  Google Scholar 

  29. Turpeinen O, Karvonen MJ, Pekkarinen M, et al. Dietary prevention of coronary heart disease: the Finnish Mental Hospital study. Int J Epidemiol 1979;8:99–118.

    Article  PubMed  CAS  Google Scholar 

  30. Miettinen M, Turpeinen O, Karvonen MJ, et al. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes: a twelve-year clinical trial in men and women. Lancet 1972;2:835–38.

    Article  PubMed  CAS  Google Scholar 

  31. Stamler J. Acute myocardial infarction: progress in primary prevention. Br Heart J 1971;33:145–64.

    Article  PubMed  Google Scholar 

  32. Frantz ID, Dawson EA, Kuba K. The Minnesota Coronary Survey: effect of diet on cardiovascular events and deaths (abstr). Circulation 1975;52(suppl II):4.

    Google Scholar 

  33. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069–1118.

    Article  Google Scholar 

  34. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980;2:379–85.

    Google Scholar 

  35. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;2:600–604.

    Google Scholar 

  36. Lipid Research Clinics Program. The Coronary Primary Prevention Trial: design and implementation. J Chronic Dis 1979;32:609–631.

    Article  Google Scholar 

  37. Lipid Research Clinics Program. Pre-entry characteristics of participants in the Lipid Research Clinics Coronary Primary Prevention Trial. J Chron Dis 1983;36:467–79.

    Article  Google Scholar 

  38. Lipid Research Clinics Program. Participant recruitment to the Coronary Primary Prevention Trial. J Chronic Dis 1983;36:451–65.

    Article  Google Scholar 

  39. Kolata G. Heart panel’s conclusions questioned. Science 1985;227:40–41.

    Article  PubMed  CAS  Google Scholar 

  40. Kronmal RA. Commentary on the published results of the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1985;253:2091–93.

    Article  PubMed  CAS  Google Scholar 

  41. Lipid Research Clinics Program Investigators. Reply to commentary by Richard Kronmal. JAMA 1985;254:263–64.

    Article  Google Scholar 

  42. Rahimtoola SH. Some unexpected lessons from large multicenter randomized clinical trials. Circulation 1985;72:449–55.

    Article  PubMed  CAS  Google Scholar 

  43. Borhani NO. Prevention of coronary heart disease in practice: implications of the results of recent clinical trials. JAMA 1985;254:257–262.

    Article  PubMed  CAS  Google Scholar 

  44. Taylor WC, Pass TM, Shepard D, et al. Cholesterol reduction and life expectancy: a model incorporating multiple risk factors. Ann Intern Med 1987;106:605–14.

    PubMed  CAS  Google Scholar 

  45. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986;256:2823–28.

    Article  PubMed  CAS  Google Scholar 

  46. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986;2:933–36.

    Article  PubMed  CAS  Google Scholar 

  47. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987;257:2176–80.

    Article  PubMed  CAS  Google Scholar 

  48. Neaton JD, Kuller LH, Wentworth D, et al. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. Am Heart J 1984;108:759–70.

    Article  PubMed  CAS  Google Scholar 

  49. Harlan WR, Stross JK. An educational view of a national initiative to lower plasma lipid levels. JAMA 1985; 253:2087–90.

    Article  PubMed  CAS  Google Scholar 

  50. Wynder EL, Field F, Haley NJ. Population screening for cholesterol determination: a pilot study. JAMA 1986;256:2839–42.

    Article  PubMed  CAS  Google Scholar 

  51. Fihn SD. A prudent approach to control of cholesterol levels. JAMA 1987;258::2416–18.

    Google Scholar 

  52. Blackburn H. Public policy and dietary recommendations to reduce population level of blood cholesterol. Am J Prev Med 1985;1:3–11.

    PubMed  CAS  Google Scholar 

  53. American Heart Association. 1989 Heart Facts. Dallas: 1988.

    Google Scholar 

  54. Lefebvre RC, Hursey KG, Carleton RA. Labeling of participants in high blood pressure screening pro-grams: implications for blood cholesterol screenings. Arch Intern Med 1988;148:1993–97.

    Article  PubMed  CAS  Google Scholar 

  55. Blank DW, Hoeg JM, Kroll MH, et al. The method of determination must be considered in interpreting blood cholesterol levels. JAMA 1986;256:2767–70.

    Article  Google Scholar 

  56. Jacobs DR, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982;116:878–85.

    PubMed  Google Scholar 

  57. Wyngaarden JB. Variability in individual cholesterol level clouds risk assessment. JAMA 1988;260:759.

    Google Scholar 

  58. Serum Cholesterol Determinations. Med Lett 1987;29:41–42.

    Google Scholar 

  59. Burke JJ II, Fischer PM. A clinician’s guide to the office measurement of cholesterol. JAMA 1988;259:3444–48.

    Article  PubMed  CAS  Google Scholar 

  60. Koch TR, Mehta U, Lee H, et al. Bias and precision of cholesterol analysis by physician’s office analyzers. Clin Chem 1987;33:2262–67.

    PubMed  CAS  Google Scholar 

  61. Kroll MH, Lindsey H, Greene J, et al. Bias between enzymatic methods and the reference method for cholesterol. Clin Chem 1988;34:131–35.

    PubMed  CAS  Google Scholar 

  62. Rastam L, Admire JB, Frantz ID, et al. Measurement of blood cholesterol with the Reflotron analyzer evaluated. Clin Chem 1988;34:26.

    Google Scholar 

  63. Hicks JM, Iosefsohn M. Another physician’s office analyzer: the Abbott “Vision” evaluated. Clin Chem 1987;33:817– 19.

    PubMed  CAS  Google Scholar 

  64. Nanji AA, Sincennes F, Poon R, et al. Evaluation of the Boehringer Mannheim “Reflotron” analyzer. Clin Chem 1987;33:1254–55.

    PubMed  CAS  Google Scholar 

  65. von Schenck H, Treichl L, Tilling B, et al. Laboratory and field evaluation of three desktop instruments for assay of cholesterol and triglyceride. Clin Chem 1987;33:1230–32.

    Google Scholar 

  66. Lasater TM, Lefebvre RC, Assaf AR, et al. Rapid measurement of blood cholesterol: evaluation of a new instrument. Am J Prev Med 1987;3:311–16.

    PubMed  CAS  Google Scholar 

  67. Belsey R, Vandenbark M, Goitein RK, et al. Evaluation of a laboratory system intended for use in physicians’ offices: II. Reliability of results produced by health care workers without formal or professional training. JAMA 1987;258:357–61.

    Article  PubMed  CAS  Google Scholar 

  68. Laboratory Standardization Panel of the National Cholesterol Education Program. Current status of blood cholesterol measurement in clinical laboratories in the United States. Clin Chem 1988;34:193–201.

    Google Scholar 

  69. Cotton P. CAP moves to improve lipid tests. Medical World News 1988 (June):55.

    Google Scholar 

  70. Oliver MF. Risks of correcting the risks of coronary disease and stroke with drugs. N Engl J Med 1982;306:297–98.

    Article  PubMed  CAS  Google Scholar 

  71. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10–32.

    PubMed  CAS  Google Scholar 

  72. Oster G, Epstein AM. Cost-effectiveness of anti hyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987;258:2381–87.

    Article  PubMed  CAS  Google Scholar 

  73. Lovastatin for hypercholesterolemia. Med Lett 1987;29:99–101.

    Google Scholar 

  74. Blum CB, Levy RI. Current therapy for hyper-cholesterolemia. JAMA 1989;261:3582–87.

    Article  PubMed  CAS  Google Scholar 

  75. Peterson B, Trell E, Sternby NH. Low cholesterol level as risk factor for noncoronary death in middle-aged men. JAMA 1981;245:2056–57.

    Article  PubMed  CAS  Google Scholar 

  76. Miller SR, Tartter PI, Papatestas AE, et al. Serum cholesterol and human colon cancer. JNCI 1981;67:297–300.

    PubMed  CAS  Google Scholar 

  77. Rose G, Shipley MJ. Plasma lipids and mortality: a source of error. Lancet 1980;2:523–526.

    Article  Google Scholar 

  78. Neugut Al, Johnsen CM, Fink DJ. Serum cholesterol levels in adenomatous polyps and cancer of the colon: a case-control study. JAMA 1986;255:365–67.

    Article  PubMed  CAS  Google Scholar 

  79. International Collaborative Group. Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years. JAMA 1982;248:2853–59.

    Article  Google Scholar 

  80. Williams RR, Sorlie PD, Feinleib M, et al. Cancer incidence by levels of cholesterol. JAMA 1981;245:247–252.

    Article  PubMed  CAS  Google Scholar 

  81. Sherwin RW, Wentworth DN, Cutler JA, et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA 1987;257:943–48.

    Article  PubMed  CAS  Google Scholar 

  82. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835–38.

    Article  PubMed  CAS  Google Scholar 

  83. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality: the Framingham Heart study. Arteriosclerosis 1988;8:737–41.

    Article  PubMed  CAS  Google Scholar 

  84. Herman M. Health Care Financing Administration. Personal communication, February 1989.

    Google Scholar 

Download references

Authors
  1. Steven H. Woolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Izaak Walton Killam Hospital for Children, Dalhousie University, B3J 3G9, Halifax, Nova Scotia, Canada

    Richard B. Goldbloom M.D. (Professor of Pediatrics) (Professor of Pediatrics)

  2. The Cambridge Hospital, Harvard Medical School, 02139, Cambridge, Massachusetts, USA

    Robert S. Lawrence M.D. (Charles S. Davidson Associate Professor of Medicine, Chief of Medicine) (Charles S. Davidson Associate Professor of Medicine, Chief of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Woolf, S.H. (1990). Elevated Serum Cholesterol in Asymptomatic Adults. In: Goldbloom, R.B., Lawrence, R.S. (eds) Preventing Disease. Frontiers of Primary Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3280-3_40

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-3280-3_40

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7948-8

  • Online ISBN: 978-1-4612-3280-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation